Global Monoamine Oxidase Type B (MAO-BI) Inhibitors Market Growth (Status and Outlook) 2025-2031
Description
The global Monoamine Oxidase Type B (MAO-BI) Inhibitors market size is predicted to grow from US$ 356 million in 2025 to US$ 452 million in 2031; it is expected to grow at a CAGR of 4.0% from 2025 to 2031.
Monoamine Oxidase Type B Inhibitors (MAO-BIs) are a class of drugs that selectively inhibit the activity of the monoamine oxidase B enzyme, which is responsible for breaking down dopamine in the brain. By preventing dopamine degradation, MAO-B inhibitors help increase dopamine levels, making them effective in the treatment of neurodegenerative disorders such as Parkinson’s disease. Common MAO-B inhibitors include selegiline, rasagiline. These drugs are often used alone in the early stages of Parkinson’s or in combination with other treatments to enhance their therapeutic effects.
United States market for Monoamine Oxidase Type B (MAO-BI) Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Monoamine Oxidase Type B (MAO-BI) Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Monoamine Oxidase Type B (MAO-BI) Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Monoamine Oxidase Type B (MAO-BI) Inhibitors players cover Fujimoto, Orion Corporation, Viatris, chiesi, Apotex, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Monoamine Oxidase Type B (MAO-BI) Inhibitors Industry Forecast” looks at past sales and reviews total world Monoamine Oxidase Type B (MAO-BI) Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Monoamine Oxidase Type B (MAO-BI) Inhibitors sales for 2025 through 2031. With Monoamine Oxidase Type B (MAO-BI) Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Monoamine Oxidase Type B (MAO-BI) Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Monoamine Oxidase Type B (MAO-BI) Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Monoamine Oxidase Type B (MAO-BI) Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Monoamine Oxidase Type B (MAO-BI) Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Monoamine Oxidase Type B (MAO-BI) Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Monoamine Oxidase Type B (MAO-BI) Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Monoamine Oxidase Type B (MAO-BI) Inhibitors market by product type, application, key players and key regions and countries.
Segmentation by Type:
Selegiline
Rasagiline
Segmentation by Application:
Hospital
Retail Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Fujimoto
Orion Corporation
Viatris
chiesi
Apotex
Lvye Pharma
Abbott
Kyowa Pharmaceutical
Bausch Health
Intas Pharmaceutical
Teva
Takeda Pharmaceutical
Qilu Pharma
Lundbeck A/S
Sun Pharmaceutical
Please note: The report will take approximately 2 business days to prepare and deliver.
Monoamine Oxidase Type B Inhibitors (MAO-BIs) are a class of drugs that selectively inhibit the activity of the monoamine oxidase B enzyme, which is responsible for breaking down dopamine in the brain. By preventing dopamine degradation, MAO-B inhibitors help increase dopamine levels, making them effective in the treatment of neurodegenerative disorders such as Parkinson’s disease. Common MAO-B inhibitors include selegiline, rasagiline. These drugs are often used alone in the early stages of Parkinson’s or in combination with other treatments to enhance their therapeutic effects.
United States market for Monoamine Oxidase Type B (MAO-BI) Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
China market for Monoamine Oxidase Type B (MAO-BI) Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Europe market for Monoamine Oxidase Type B (MAO-BI) Inhibitors is estimated to increase from US$ million in 2024 to US$ million by 2031, at a CAGR of % from 2025 through 2031.
Global key Monoamine Oxidase Type B (MAO-BI) Inhibitors players cover Fujimoto, Orion Corporation, Viatris, chiesi, Apotex, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2024.
LPI (LP Information)' newest research report, the “Monoamine Oxidase Type B (MAO-BI) Inhibitors Industry Forecast” looks at past sales and reviews total world Monoamine Oxidase Type B (MAO-BI) Inhibitors sales in 2024, providing a comprehensive analysis by region and market sector of projected Monoamine Oxidase Type B (MAO-BI) Inhibitors sales for 2025 through 2031. With Monoamine Oxidase Type B (MAO-BI) Inhibitors sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Monoamine Oxidase Type B (MAO-BI) Inhibitors industry.
This Insight Report provides a comprehensive analysis of the global Monoamine Oxidase Type B (MAO-BI) Inhibitors landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Monoamine Oxidase Type B (MAO-BI) Inhibitors portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Monoamine Oxidase Type B (MAO-BI) Inhibitors market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Monoamine Oxidase Type B (MAO-BI) Inhibitors and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Monoamine Oxidase Type B (MAO-BI) Inhibitors.
This report presents a comprehensive overview, market shares, and growth opportunities of Monoamine Oxidase Type B (MAO-BI) Inhibitors market by product type, application, key players and key regions and countries.
Segmentation by Type:
Selegiline
Rasagiline
Segmentation by Application:
Hospital
Retail Pharmacy
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Fujimoto
Orion Corporation
Viatris
chiesi
Apotex
Lvye Pharma
Abbott
Kyowa Pharmaceutical
Bausch Health
Intas Pharmaceutical
Teva
Takeda Pharmaceutical
Qilu Pharma
Lundbeck A/S
Sun Pharmaceutical
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
108 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Monoamine Oxidase Type B (MAO-BI) Inhibitors Market Size by Player
- 4 Monoamine Oxidase Type B (MAO-BI) Inhibitors by Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Global Monoamine Oxidase Type B (MAO-BI) Inhibitors Market Forecast
- 11 Key Players Analysis
- 12 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
